DS
RXRX icon

David Shaw’s Recursion Pharmaceuticals RXRX Stock Holding History

David Shaw’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$139K Sell
37,914
-8,094
-18% -$26.9K ﹤0.01% 4593
2026
Q1 		$141K Sell
46,008
-43,536
-49% -$168K ﹤0.01% 4246
2025
Q4 		$366K Buy
+89,544
New +$444K ﹤0.01% 4068
2025
Q3 		– Sell
-633,403
Closed -$3.21M – 4871
2025
Q2 		$3.21M Buy
633,403
+572,497
+940% +$2.81M ﹤0.01% 2376
2025
Q1 		$322K Buy
+60,906
New +$444K ﹤0.01% 3734
2024
Q2 		– Sell
-61,963
Closed -$618K – 4800
2024
Q1 		$618K Buy
61,963
+46,904
+311% +$522K ﹤0.01% 3382
2023
Q4 		$148K Sell
15,059
-8,648
-36% -$61.7K ﹤0.01% 3925
2023
Q3 		$181K Buy
23,707
+11,862
+100% +$118K ﹤0.01% 3783
2023
Q2 		$88.5K Sell
11,845
-191,053
-94% -$1.34M ﹤0.01% 3839
2023
Q1 		$1.35M Buy
+202,898
New +$1.61M ﹤0.01% 2954

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

David Shaw's RXRX Position: Q2 2026 in Review

David Shaw reduced its Recursion Pharmaceuticals (RXRX) stake by 18% in Q2 2026, selling an estimated $26.9K and leaving 37,914 shares worth $139K. The position accounts for ﹤0.01% of the portfolio, ranked #4593.

David Shaw first reported a position in RXRX in Q1 2023 and has held it in 10 quarters since. The position peaked at $3.21M in Q2 2025. 339 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • David Shaw held 37,914 shares of Recursion Pharmaceuticals worth $139K as of Q2 2026.
  • David Shaw sold 8,094 Recursion Pharmaceuticals shares in Q2 2026, an estimated $26.9K.
  • Recursion Pharmaceuticals made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4593 holding.
  • David Shaw first reported a position in Recursion Pharmaceuticals in Q1 2023 and has held it in 10 quarters since.
  • David Shaw's Recursion Pharmaceuticals position peaked at $3.21M in Q2 2025.
  • 339 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.